Signal Transduction and Targeted Therapy (Jun 2024)

Nonconserved epitopes dominate reverse preexisting T cell immunity in COVID-19 convalescents

  • Xin Wang,
  • Jie Zhang,
  • Maoshun Liu,
  • Yuanyuan Guo,
  • Peipei Guo,
  • Xiaonan Yang,
  • Bingli Shang,
  • Min Li,
  • Jinmin Tian,
  • Ting Zhang,
  • Xi Wang,
  • Ronghua Jin,
  • Jikun Zhou,
  • George F. Gao,
  • Jun Liu

DOI
https://doi.org/10.1038/s41392-024-01876-3
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 15

Abstract

Read online

Abstract The herd immunity against SARS-CoV-2 is continuously consolidated across the world during the ongoing pandemic. However, the potential function of the nonconserved epitopes in the reverse preexisting cross-reactivity induced by SARS-CoV-2 to other human coronaviruses is not well explored. In our research, we assessed T cell responses to both conserved and nonconserved peptides shared by SARS-CoV-2 and SARS-CoV, identifying cross-reactive CD8+ T cell epitopes using enzyme-linked immunospot and intracellular cytokine staining assays. Then, in vitro refolding and circular dichroism were performed to evaluate the thermal stability of the HLA/peptide complexes. Lastly, single-cell T cell receptor reservoir was analyzed based on tetramer staining. Here, we discovered that cross-reactive T cells targeting SARS-CoV were present in individuals who had recovered from COVID-19, and identified SARS-CoV-2 CD8+ T cell epitopes spanning the major structural antigens. T cell responses induced by the nonconserved peptides between SARS-CoV-2 and SARS-CoV were higher and played a dominant role in the cross-reactivity in COVID-19 convalescents. Cross-T cell reactivity was also observed within the identified series of CD8+ T cell epitopes. For representative immunodominant peptide pairs, although the HLA binding capacities for peptides from SARS-CoV-2 and SARS-CoV were similar, the TCR repertoires recognizing these peptides were distinct. Our results could provide beneficial information for the development of peptide-based universal vaccines against coronaviruses.